Evidence map›Paper›PMID 38681824›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2024

Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.

Atsuhiro Morita, Nobuharu Tamaki, Haruhiko Kobashi, Nami Mori, Keiji Tsuji, Shintaro Takaki, Chitomi Hasebe, Takehiro Akahane, Hironori Ochi, Toshie Mashiba and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Atsuhiro MoritaDepartment of Gastroenterology Japanese Red Cross Kyoto Daini Hospital Kyoto Japan.
Nobuharu TamakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Haruhiko KobashiDepartment of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Japan.
Nami MoriDepartment of Gastroenterology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Japan.
Keiji TsujiDepartment of Gastroenterology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Japan.
Shintaro TakakiDepartment of Gastroenterology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Japan.
Chitomi HasebeDepartment of Gastroenterology Japanese Red Cross Asahikawa Hospital Asahikawa Japan.
Takehiro AkahaneDepartment of Gastroenterology Ishinomaki Red Cross Hospital Ishinomaki Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan.
Toshie MashibaCenter for Liver-Biliary-Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan.
Naohito UrawaDepartment of Gastroenterology and Hepatology Ise Red Cross Hospital Ise Japan.
Hideki FujiiDepartment of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
Akeri MitsudaDepartment of Gastroenterology Tottori Red Cross Hospital Tottori Japan.
Masahiko KondoDepartment of Gastroenterology Otsu Red Cross Hospital Otsu Japan.
Chikara OgawaDepartment of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Japan.
Yasushi UchidaDepartment of Gastroenterology Matsue Red Cross Hospital Matsue Japan.
Ryoichi NaritaDepartment of Gastroenterology Oita Red Cross Hospital Oita Japan.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology Osaka Red Cross Hospital Osaka Japan.
Yoshihito KubotsuDepartment of Internal Medicine Karatsu Red Cross Hospital Saga Japan.
Tomomichi MatsushitaDepartment of Gastroenterology Japanese Red Cross Gifu Hospital Gifu Japan.
Masaya ShigenoDepartment of Gastroenterology Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan.
Hideo YoshidaDepartment of Gastroenterology Japanese Red Cross Medical Center Tokyo Japan.
Katsuaki TanakaDepartment of Gastroenterology Hatano Red Cross Hospital Hatano Japan.
Eisuke OkamotoDepartment of Gastroenterology Masuda Red Cross Hospital Masuda Japan.
Toyotaka KasaiDepartment of Gastroenterology Fukaya Red Cross Hospital Saitama Japan.
Toru IshiiDepartment of Gastroenterology Japanese Red Cross Akita Hospital Akita Japan.
Kazuhiko OkadaDepartment of Gastroenterology Toyama Red Cross Hospital Toyama Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non-cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated. Methods: This prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non-cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated. Results: The SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups ( Conclusion: GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision.

Indexed as

chronic hepatitis Ccirrhosisglecaprevir and pibrentasvir (GLE/PIB)treatment periods

Identifiers

PMID38681824
PMCPMC11046085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.